Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib in RA with inadequate response to csDMARDs (SELECT-NEXT)
NCT02675426Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Dec 2015
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 38
01
Overview
A Phase 3 trial of upadacitinib in rheumatoid arthritis (RA), sponsored by AbbVie Inc.. Started Dec 2015; status: completed.
02
Drugs
upadacitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02675426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02675426.